Highlights on the recent clinical studies and inventions in the use of natural products in the management of Covid-19

Authors

  • Zia Ur Rehman Health Research Centre, Jazan University, P.O. Box 114, Jazan 45142, Saudi Arabia. Department of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmacy, Jazan University, P.O. Box 114, Jazan 45142, Saudi Arabia.
  • Khadiga G Abd Elaleem Department of Biology and Biotechnology, Faculty of Science and Technology, AL Neelain University, Khartoum, Sudan.
  • Ahlam S Mohamed Department of Biology, Faculty of Science, Hafr Elbatin University, Hafr Elbatin, Saudi Arabia.
  • Hayat Ali Alzahrani Department of Medical Laboratory Technology, College of Applied Medical Sciences, Northern Border University, Arar, Saudi Arabia.
  • Nada Omar Salim Binzager Jeddah Regional Laboratory, Jeddah, Saudi Arabia.
  • Hafeezullah Wazir Ali Department of Physiology, College of Medicine, Northern Border University, Arar, Saudi Arabia.
  • Khalid Hassan Almohammed Department of Pharmaceutics, College of Pharmacy, Northern Border University, Rafha, Saudi Arabia.
  • Mohd Imran Department of Pharmaceutical Chemistry, College of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia. Center for Health Research, Northern Border University, Arar, Saudi Arabia.

DOI:

https://doi.org/10.47552/ijam.v16i3.5828

Keywords:

Natural products, COVID-19, SARS-CoV-2, Clinical studies, Patents

Abstract

Natural products (NPs), long regarded for their medical qualities, have recently seen a rise in interest as the world seeks viable therapies and prevention measures for COVID-19. Many reports have been published on the role of NPs in managing COVID-19. This article highlights the recent noteworthy clinical developments and inventions concerning the application of NPs to manage the COVID-19 pandemic. The non-patent literature for this review was obtained from PubMed, whereas patent information was obtained from the Espacenet databases. Recent clinical trials have explored the role of many NPs (spirulina; curcumin + piperine; xanthohumol; CurcuRouge®; virgin coconut oil; thyme oil; licorice extract; pomegranate juice; Ayurvedic and Chinese herbal formulations) in managing COVID-19. Multiple NPs formulations and compositions (dieckol; isobracin; phloroglucinol compounds; propolis + xylitol; Virofree TM; NRICM102; Terminalia chebula tannic acid + punicalagin; Cypress tree extract + Chlorine dioxide; Saussurea costus) with antiviral and immune-boosting potential have been recently patented for use in COVID-19 management. Many inventions are foreseeable, including new delivery systems of existing anti-COVID-19 NPs, derivatives of anti-COVID-19 NPs, drug repurposing of the marketed NPs, and new combinations (two or more NPs; NPs + existing anti-COVID-19 drugs; NPs + vaccine; NPs + monoclonal antibodies). Nonetheless, there is a great deal of room for innovation in the use of NPs in the control of COVID-19. Accordingly, NPs have the potential to play an increasingly important role in global healthcare to manage COVID-19 as studies continue.

Downloads

Published

2025-09-30

How to Cite

Rehman, Z. U., Abd Elaleem, K. G., Mohamed, A. S., Alzahrani, H. A., Binzager, N. O. S., Ali, H. W., … Imran, M. (2025). Highlights on the recent clinical studies and inventions in the use of natural products in the management of Covid-19. International Journal of Ayurvedic Medicine, 16(3), 583–590. https://doi.org/10.47552/ijam.v16i3.5828

Issue

Vol. 16 No. 3 (2025): July - September 2025

Section

Review Articles

License

Copyright (c) 2025 International Journal of Ayurvedic Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The author hereby transfers, assigns, or conveys all copyright ownership to the International Journal of Ayurvedic Medicine (IJAM). By this transfer, the article becomes the property of the IJAM and may not be published elsewhere without written permission from the IJAM.

This transfer of copyright also implies transfer of rights for printed, electronic, microfilm, and facsimile publication. No royalty or other monetary compensation will be received for transferring the copyright of the article to the IJAM.

The IJAM, in turn, grants each author the right to republish the article in any book for which he or she is the author or editor, without paying royalties to the IJAM, subject to the express conditions that (a) the author notify IJAM in advance in writing of this republication and (b) a credit line attributes the original publication to IJAM.

https://creativecommons.org/licenses/by-nc-sa/4.0/